Adaptin Bio (APTN) Net Cash Flow (2024 - 2026)

Adaptin Bio (APTN) has 3 years of Net Cash Flow data on file, last reported at -$157865.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 106.75% year-over-year to -$157865.0; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (down 187.5% YoY), and the FY2025 full-year result was $425089.0, up 1349.28% from the prior year.
• Net Cash Flow declined to -$157865.0 in Q1 2026, from -$119915.0 in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $2.3 million in Q1 2025 to a low of -$1.0 million in Q2 2025.
• A 3-year average of $32950.6 and a median of -$81223.0 in 2024 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 767160.33% in 2025, while the deepest fall reached 5564.07% in 2025.
• Tracing APTN's Net Cash Flow over 3 years: stood at -$81223.0 in 2024, then tumbled by 47.64% to -$119915.0 in 2025, then plunged by 31.65% to -$157865.0 in 2026.
• Business Quant data shows APTN's Net Cash Flow at -$157865.0 in Q1 2026, -$119915.0 in Q4 2025, and -$772430.0 in Q3 2025.